Pharmaceuticals (Oct 2022)

Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarcinoma

  • Jia-Hao Zheng,
  • Hong-Fei Yao,
  • Zong-Hao Duan,
  • Pei-Xuan Ji,
  • Jian Yang,
  • Yu-Heng Zhu,
  • Qin-Yuan Jia,
  • Jian-Yu Yang,
  • De-Jun Liu,
  • Yong-Wei Sun,
  • Peng-Cheng Chen,
  • Pei-Dong Shi,
  • Li Chen

DOI
https://doi.org/10.3390/ph15111336
Journal volume & issue
Vol. 15, no. 11
p. 1336

Abstract

Read online

Pancreatic adenocarcinoma (PAAD), one of the most malignant tumors, not only has abundant mesenchymal components, but is also characterized by an extremely high metastatic risk. The purpose of this study was to construct a model of stroma- and metastasis-associated prognostic signature, aiming to benefit the existing clinical staging system and predict the prognosis of patients. First, stroma-associated genes were screened from the TCGA database with the ESTIMATE algorithm. Subsequently, transcriptomic data from clinical tissues in the RenJi cohort were screened for metastasis-associated genes. Integrating the two sets of genes, we constructed a risk prognostic signature by Cox and LASSO regression analysis. We then obtained a risk score by a quantitative formula and divided all samples into high- and low-risk groups based on the scores. The results demonstrated that patients with high-risk scores have a worse prognosis than those with low-risk scores, both in the TCGA database and in the RenJi cohort. In addition, tumor mutation burden, chemotherapeutic drug sensitivity and immune infiltration analysis also exhibited significant differences between the two groups. In exploring the potential mechanisms of how stromal components affect tumor metastasis, we simulated different matrix stiffness in vitro to explore its effect on EMT key genes in PAAD cells. We found that cancer cells stimulated by high matrix stiffness may trigger EMT and promote PAAD metastasis.

Keywords